172 related articles for article (PubMed ID: 27002940)
1. Prognostic role of ERBB2, MET and VEGFA expression in metastatic colorectal cancer patients treated with anti-EGFR antibodies.
Takahashi N; Iwasa S; Taniguchi H; Sasaki Y; Shoji H; Honma Y; Takashima A; Okita N; Kato K; Hamaguchi T; Shimada Y; Yamada Y
Br J Cancer; 2016 Apr; 114(9):1003-11. PubMed ID: 27002940
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy.
Llovet P; Sastre J; Ortega JS; Bando I; Ferrer M; García-Alfonso P; Donnay O; Carrato A; Jiménez A; Aranda E; León A; Grávalos C; Cámara JC; Feliú J; Sanchíz B; Caldés T; Díaz-Rubio E
Mol Diagn Ther; 2015 Dec; 19(6):397-408. PubMed ID: 26341080
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of amphiregulin and epiregulin mRNA expression in metastatic colorectal cancer patients.
Jing C; Jin YH; You Z; Qiong Q; Jun Z
Oncotarget; 2016 Aug; 7(34):55890-55899. PubMed ID: 27344184
[TBL] [Abstract][Full Text] [Related]
4. Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial).
Stahler A; Heinemann V; Giessen-Jung C; Crispin A; Schalhorn A; Stintzing S; Fischer von Weikersthal L; Vehling-Kaiser U; Stauch M; Quietzsch D; Held S; von Einem JC; Holch J; Neumann J; Kirchner T; Jung A; Modest DP
Int J Cancer; 2016 Feb; 138(3):739-46. PubMed ID: 26284333
[TBL] [Abstract][Full Text] [Related]
5. Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).
Cushman SM; Jiang C; Hatch AJ; Shterev I; Sibley AB; Niedzwiecki D; Venook AP; Owzar K; Hurwitz HI; Nixon AB
Clin Cancer Res; 2015 Mar; 21(5):1078-86. PubMed ID: 25520391
[TBL] [Abstract][Full Text] [Related]
6. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab.
Jacobs B; De Roock W; Piessevaux H; Van Oirbeek R; Biesmans B; De Schutter J; Fieuws S; Vandesompele J; Peeters M; Van Laethem JL; Humblet Y; Pénault-Llorca F; De Hertogh G; Laurent-Puig P; Van Cutsem E; Tejpar S
J Clin Oncol; 2009 Oct; 27(30):5068-74. PubMed ID: 19738126
[TBL] [Abstract][Full Text] [Related]
7. Association between serum ligands and the skin toxicity of anti-epidermal growth factor receptor antibody in metastatic colorectal cancer.
Takahashi N; Yamada Y; Furuta K; Nagashima K; Kubo A; Sasaki Y; Shoji H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Hamaguchi T; Shimada Y
Cancer Sci; 2015 May; 106(5):604-10. PubMed ID: 25707609
[TBL] [Abstract][Full Text] [Related]
8. Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer.
Seligmann JF; Hatch AJ; Richman SD; Elliott F; Jacobs B; Brown S; Hurwitz H; Barrett JH; Quirke P; Nixon AB; Seymour MT
JAMA Oncol; 2018 Apr; 4(4):564-568. PubMed ID: 29075780
[TBL] [Abstract][Full Text] [Related]
9.
Kuramochi H; Nakajima GO; Hayashi K; Araida T; Yamamoto M
Anticancer Res; 2019 Sep; 39(9):4729-4736. PubMed ID: 31519572
[TBL] [Abstract][Full Text] [Related]
10. Combined assessment of EGFR-related molecules to predict outcome of 1st-line cetuximab-containing chemotherapy for metastatic colorectal cancer.
Sunakawa Y; Yang D; Moran M; Astrow SH; Tsuji A; Stephens C; Zhang W; Cao S; Takahashi T; Denda T; Shimada K; Kochi M; Nakamura M; Kotaka M; Segawa Y; Masuishi T; Takeuchi M; Fujii M; Nakajima T; Ichikawa W; Lenz HJ
Cancer Biol Ther; 2016 Jul; 17(7):751-9. PubMed ID: 27104867
[TBL] [Abstract][Full Text] [Related]
11. Amphiregulin Expression Is a Predictive Biomarker for
Stahler A; Stintzing S; Modest DP; Ricard I; Giessen-Jung C; Kapaun C; Ivanova B; Kaiser F; Fischer von Weikersthal L; Moosmann N; Schalhorn A; Stauch M; Kiani A; Held S; Decker T; Moehler M; Neumann J; Kirchner T; Jung A; Heinemann V
Clin Cancer Res; 2020 Dec; 26(24):6559-6567. PubMed ID: 32943459
[TBL] [Abstract][Full Text] [Related]
12. TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer.
Spindler KL; Christensen IJ; Nielsen HJ; Jakobsen A; Brünner N
Tumour Biol; 2015 Jun; 36(6):4301-8. PubMed ID: 25608838
[TBL] [Abstract][Full Text] [Related]
13. Amphiregulin and Epiregulin mRNA expression in primary colorectal cancer and corresponding liver metastases.
Kuramochi H; Nakajima G; Kaneko Y; Nakamura A; Inoue Y; Yamamoto M; Hayashi K
BMC Cancer; 2012 Mar; 12():88. PubMed ID: 22409860
[TBL] [Abstract][Full Text] [Related]
14. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
[TBL] [Abstract][Full Text] [Related]
15. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.
Khambata-Ford S; Garrett CR; Meropol NJ; Basik M; Harbison CT; Wu S; Wong TW; Huang X; Takimoto CH; Godwin AK; Tan BR; Krishnamurthi SS; Burris HA; Poplin EA; Hidalgo M; Baselga J; Clark EA; Mauro DJ
J Clin Oncol; 2007 Aug; 25(22):3230-7. PubMed ID: 17664471
[TBL] [Abstract][Full Text] [Related]
16. Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer.
Williams CJM; Elliott F; Sapanara N; Aghaei F; Zhang L; Muranyi A; Yan D; Bai I; Zhao Z; Shires M; Wood HM; Richman SD; Hemmings G; Hale M; Bottomley D; Galvin L; Cartlidge C; Dance S; Bacon CM; Mansfield L; Young-Zvandasara K; Sudan A; Lambert K; Bibby I; Coupland SE; Montazeri A; Kipling N; Hughes K; Cross SS; Dewdney A; Pheasey L; Leng C; Gochera T; Mangham DC; Saunders M; Pritchard M; Stott H; Mukherjee A; Ilyas M; Silverman R; Hyland G; Sculthorpe D; Thornton K; Gould I; O'Callaghan A; Brown N; Turnbull S; Shaw L; Seymour MT; West NP; Seligmann JF; Singh S; Shanmugam K; Quirke P
Clin Cancer Res; 2023 Oct; 29(20):4153-4165. PubMed ID: 37363997
[TBL] [Abstract][Full Text] [Related]
17. Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer.
Lee MS; McGuffey EJ; Morris JS; Manyam G; Baladandayuthapani V; Wei W; Morris VK; Overman MJ; Maru DM; Jiang ZQ; Hamilton SR; Kopetz S
Br J Cancer; 2016 Jun; 114(12):1352-61. PubMed ID: 27272216
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical evaluation of the prognostic and predictive power of epidermal growth factor receptor ligand levels in patients with metastatic colorectal cancer.
Foroughi S; Hutchinson RA; Wong HL; Christie M; Batrouney A; Wong R; Lee M; Tie J; Burgess AW; Gibbs P
Growth Factors; 2020; 38(3-4):127-136. PubMed ID: 33775193
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy.
Lo Nigro C; Ricci V; Vivenza D; Granetto C; Fabozzi T; Miraglio E; Merlano MC
World J Gastroenterol; 2016 Aug; 22(30):6944-54. PubMed ID: 27570430
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J; Punt CJ
Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
